Vaccines

12/21/19 – Thimerosol & Aluminum in Vaccines: MegaPost

MERCURY / US

Bullshit:

Here is a link which conatins 89 peer reviewed papers connecting autism and mercury:

https://childrenshealthdefense.org/wp-content/uploads/autism-mercury-abstracts-5.8.19.pdf


Vaccine effects wane /
Crazy numbers when no safety study has ever been done /

ALUMINUM / THIMEROSOL / CANADA

Link to 100 papers about Aluminum / Autism / Vaccines:

https://drive.google.com/file/d/0B3mMkPwF1DUPN3lnWXdyY0otVGM/view

https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-15-contents-immunizing-agents-available-use-canada.html#p1c14t1


This image has an empty alt attribute; its file name is image-883.png
Standard
Vaccines

12/20/19 – FDA Approves an Ebola Vaccine For the First Time

FDA Approves an Ebola Vaccine For the First Time

So that is the entire article from Scientific American. Before we continue here are just some small graphs that I’m going to save here for future reference:

Image result for ebola cases per year graph
Image result for ebola cases per year graph

Okay let’s look at this vaccine:

This leads to this paper published in 2016:

The presentation of this graph is that it will instill the idea that these mild reactions to the vaccine taper off to 0 in due time, but no evidence of this is provided.


So it is 100% effective, but they this isn’t a safety study. Now that they know there is a “100% efficacy rate,” where is the Vaccinated Vs. Vaccinated study, with a minimum of 3-4 year follow-up to see long term adverse events? This study only followed for 84 days. This was published online 3 years ago.

They have been using an unlicensed version already with no safety study, and will now transition to the licensed version.

Anaphylaxis and febrile reaction were causally related to the vaccine.

48% of serious adverse events were the Ebola virus disease ??



There are 3 major dates to be studied in within this vaccines lifespan to date:

12/22/2016 – Published online: Efficacy and eff ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: fi nal results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffi t!)

11/11/19 – European commission accepts the vaccine.

12/20/19 – FDA licenses the vaccine.

Standard